PTC Therapeutics Inc (PTCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.30B
Last updated: Nov 17, 2026 at 11:06 AM ET
PTC Therapeutics Inc (PTCT) Earnings: Report Dates and Results
PTC Therapeutics (PTCT) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, PTC Therapeutics reported EPS of $0.61, above the $0.17 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PTCT has an expected report date of Feb 17, 2027.
PTCT Earnings Call
The latest PTCT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, PTCT beat 14, missed 24 and matched 1. The widest gap in the table came in the quarter ended Jun 30, 2026, when EPS landed 641.18% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.61 | $0.17 | N/A | +258.82% | Beat | +221.1% | 3 | 1 up, 1 down | Oct 29, 2026 | N/A |
| Jun 30, 2026 | $0.92 | -$0.17 | N/A | +641.18% | Beat | N/A | 3 | 0 up, 0 down | Jul 30, 2026 | $360.52M |
| Mar 31, 2026 | -$0.03 | -$0.44 | -$0.44 - -$0.44 | +93.18% | Beat | -100.3% | 1 | 0 up, 1 down | May 7, 2026 | $272.55M |
| Dec 31, 2025 | -$1.80 | -$0.40 | -$1.17 - $1.23 | -350.00% | Miss | N/A | 4 | 0 up, 1 down | Feb 19, 2026 | $164.68M |
| Sep 30, 2025 | $0.19 | -$1.11 | -$1.30 - -$0.87 | +117.12% | Beat | N/A | 7 | 2 up, 2 down | Nov 4, 2025 | $211.01M |
| Jun 30, 2025 | -$0.83 | -$1.07 | -$1.27 - -$0.96 | +22.43% | Beat | N/A | 4 | 1 up, 0 down | Aug 7, 2025 | $178.88M |
| Mar 31, 2025 | $10.04 | -$0.70 | -$1.15 - -$0.26 | N/A | N/A | N/A | 2 | 1 up, 0 down | May 6, 2025 | $1.18B |
| Dec 31, 2024 | -$0.34 | -$0.65 | -$0.94 - -$0.16 | +47.45% | Beat | N/A | 3 | 2 up, 0 down | Feb 27, 2025 | $213.17M |
| Sep 30, 2024 | -$1.36 | -$1.66 | -$2.09 - -$0.91 | +18.07% | Beat | N/A | 13 | 1 up, 0 down | Nov 7, 2024 | $196.79M |
| Jun 30, 2024 | -$1.27 | -$0.95 | -$1.65 - -$0.73 | -33.68% | Miss | N/A | 12 | 2 up, 0 down | Aug 8, 2024 | $186.70M |
| Mar 31, 2024 | -$1.20 | -$1.10 | -$1.93 - -$0.56 | -9.09% | Miss | N/A | 13 | 2 up, 0 down | Apr 25, 2024 | $210.12M |
| Dec 31, 2023 | -$0.24 | $0.50 | -$1.10 - $1.47 | -148.00% | Miss | N/A | 13 | 2 up, 0 down | Feb 29, 2024 | $307.06M |
| Sep 30, 2023 | -$1.75 | -$1.55 | -$1.81 - -$0.70 | -12.90% | Miss | N/A | 12 | 2 up, 0 down | Oct 26, 2023 | $196.58M |
| Jun 30, 2023 | -$1.58 | -$1.71 | -$3.04 - -$0.58 | +7.60% | Beat | N/A | 13 | 2 up, 0 down | Aug 3, 2023 | $213.81M |
| Mar 31, 2023 | -$1.88 | -$1.63 | -$1.96 - -$0.46 | -15.34% | Miss | N/A | 16 | 2 up, 1 down | Apr 27, 2023 | $220.38M |
| Dec 31, 2022 | -$1.89 | -$1.59 | -$2.32 - -$0.22 | -18.87% | Miss | N/A | 15 | 0 up, 0 down | Feb 21, 2023 | $167.41M |
| Sep 30, 2022 | -$1.53 | -$1.26 | -$1.97 - -$0.71 | -21.43% | Miss | N/A | 14 | 1 up, 1 down | Oct 27, 2022 | $217.13M |
| Jun 30, 2022 | -$2.13 | -$1.48 | N/A | -43.92% | Miss | N/A | N/A | 1 up, 0 down | Aug 4, 2022 | $165.53M |
| Mar 31, 2022 | -$1.78 | -$1.66 | -$2.10 - -$1.06 | -7.23% | Miss | N/A | 10 | 4 up, 0 down | May 3, 2022 | $148.74M |
| Dec 31, 2021 | -$2.03 | -$1.65 | -$2.60 - -$1.04 | -23.03% | Miss | N/A | 11 | 3 up, 0 down | Feb 22, 2022 | $165.23M |
| Sep 30, 2021 | -$1.89 | -$1.89 | -$2.14 - $0.05 | 0.00% | In line | N/A | 10 | 2 up, 0 down | Oct 28, 2021 | $138.74M |
| Jun 30, 2021 | -$1.68 | -$1.82 | -$2.11 - -$1.50 | +7.69% | Beat | N/A | 9 | N/A | Jul 29, 2021 | $116.68M |
| Mar 31, 2021 | -$1.83 | -$1.62 | -$2.05 - -$1.13 | -12.96% | Miss | N/A | 11 | N/A | May 4, 2021 | $117.94M |
| Dec 31, 2020 | -$1.08 | -$0.94 | -$1.58 - -$0.23 | -14.89% | Miss | N/A | 12 | N/A | Feb 25, 2021 | $237.27M |
| Sep 30, 2020 | -$1.03 | -$0.45 | -$2.12 - $9.14 | -128.89% | Miss | N/A | 13 | N/A | Oct 29, 2020 | N/A |
| Jun 30, 2020 | -$1.80 | -$1.56 | -$1.72 - -$0.93 | -15.38% | Miss | N/A | 10 | N/A | Aug 5, 2020 | $75.24M |
| Mar 31, 2020 | -$1.81 | -$1.33 | -$1.73 - -$0.92 | -36.09% | Miss | N/A | 9 | N/A | Apr 30, 2020 | $68.26M |
| Dec 31, 2019 | -$1.37 | -$0.71 | -$0.78 - -$0.16 | -92.96% | Miss | N/A | 9 | N/A | Mar 2, 2020 | $96.46M |
| Sep 30, 2019 | -$0.89 | -$0.88 | -$0.92 - -$0.45 | -1.14% | Miss | N/A | 9 | N/A | Oct 29, 2019 | $71.42M |
| Jun 30, 2019 | -$0.65 | -$0.61 | -$0.88 - -$0.35 | -6.56% | Miss | N/A | 9 | N/A | Aug 6, 2019 | $85.52M |
| Mar 31, 2019 | -$0.91 | -$0.68 | -$0.83 - -$0.60 | -33.82% | Miss | N/A | 7 | N/A | May 2, 2019 | $53.58M |
| Dec 31, 2018 | -$0.58 | -$0.32 | -$0.47 - -$0.11 | -81.25% | Miss | -2033.3% | 7 | N/A | Feb 28, 2019 | $32.75M |
| Sep 30, 2018 | -$1.06 | -$0.49 | -$0.68 - -$0.11 | -116.33% | Miss | N/A | 8 | N/A | Nov 5, 2018 | $107.18M |
| Jun 30, 2018 | -$0.21 | -$0.44 | -$0.45 - -$0.04 | +52.27% | Beat | N/A | 6 | N/A | Aug 7, 2018 | $68.74M |
| Mar 31, 2018 | -$0.46 | -$0.38 | -$0.71 - -$0.19 | -21.05% | Miss | N/A | 6 | N/A | May 9, 2018 | $56.06M |
| Dec 31, 2017 | $0.03 | -$0.14 | -$0.69 - $0.10 | +121.43% | Beat | N/A | 7 | N/A | Mar 6, 2018 | $78.03M |
| Sep 30, 2017 | -$0.82 | -$0.67 | -$0.94 - -$0.29 | -22.39% | Miss | N/A | 7 | N/A | Nov 2, 2017 | $41.85M |
| Jun 30, 2017 | -$0.44 | -$0.86 | -$2.82 - -$0.81 | +48.84% | Beat | N/A | 5 | N/A | Aug 8, 2017 | $47.96M |
| Mar 31, 2017 | -$0.85 | -$0.93 | N/A | +8.60% | Beat | N/A | N/A | N/A | May 8, 2017 | $26.55M |
| Dec 31, 2016 | -$0.78 | -$1.07 | N/A | +27.10% | Beat | N/A | N/A | N/A | Mar 16, 2017 | $25.19M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $7.60, a profit after a loss of $4.17 per share the year before. It was -$4.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $7.60 | N/A |
| Dec 31, 2024 | -$4.17 | N/A |
| Dec 31, 2023 | -$5.45 | N/A |
| Dec 31, 2022 | -$7.33 | N/A |
| Dec 31, 2021 | -$7.43 | N/A |
| Dec 31, 2020 | -$5.72 | N/A |
| Dec 31, 2019 | -$3.82 | N/A |
| Dec 31, 2018 | -$2.31 | N/A |
| Dec 31, 2017 | -$2.08 | N/A |
| Dec 31, 2016 | -$4.17 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,200 words across 19 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,218 | 19 | |
| 2026Q2 | Jun 30, 2026 | 9,014 | 18 | |
| 2026Q1 | Mar 31, 2026 | 6,729 | 18 | |
| 2025Q4 | Dec 31, 2025 | 8,568 | 17 | |
| 2025Q3 | Sep 30, 2025 | 6,994 | 18 | |
| 2025Q2 | Jun 30, 2025 | 7,805 | 21 | |
| 2025Q1 | Mar 31, 2025 | 7,870 | 13 | |
| 2024Q4 | Dec 31, 2024 | 8,801 | 19 |
2026Q3 Earnings Call
Opening remarks
Ellen Cavaleri Head of Investor Relations Good afternoon, and thank you for joining us to discuss PTC Therapeutics' Third Quarter 2026 Corporate Update and Financial Results. I am joined today by our Chief Executive Officer, Dr. Matthew Klein; our Chief Business Officer, Eric Pauwels; and our Chief Financial Officer, Pierre Gravier. Today's call will include forward-looking statements based on our current expectations. These statements are subject to certain risks and uncertainties, and actual results may differ materially. Please review the slide posted on our Investor Relations website in conjunction with the call, which contains information about our forward-looking statements and our most recent quarterly report on Form 10-Q and annual report on Form 10-K filed with the SEC, as well as our other SEC filings, for a detailed description of applicable risks and uncertainties that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. Additionally, we will disclose certain non-GAAP information during this call. Information regarding our use of GAAP to non-GAAP financial measures and reconciliation of GAAP to non-GAAP are available in today's earnings release. I will now pass the call over to our CEO, Dr. Matthew Klein.
Matthew Klein CEO Thank you all for joining us today. I'm pleased to share the results of another quarter of record product revenue and solid execution across the company. In the third quarter, we achieved total revenue of $358 million, including $276 million of product revenue, led by continued quarter-over-quarter growth of Sephience sales in the U.S. and internationally. Based on this performance, we are raising our full-year 2026 product revenue guidance to $960 million to $990 million and now expect total revenue of $1.29 billion to $1.32 billion. This updated guidance represents 64% to 69% year-over-year product revenue growth. In addition, with our continued effective expense management, we expect to achieve our goal of reaching cash flow breakeven in 2026. Beginning with Sephience, we are now one year into the global launch, which by all measures has been a great success, and all signs point to Sephience being a blockbuster rare disease product. In the third quarter, worldwide Sephience revenue was $182 million, led by consistent growth in the U.S. and continued expansion internationally. As of September 30, we have over 2,000 active patients on Sephience worldwide. In the U.S., we continue to see strong underlying demand across all patient segments. Over the course of the third quarter, we saw an uptick in branded and generic Kuvan switches, with continued penetration into the therapy-naive and tried-and-failed patient segments. Adherence remains strong, reinforcing the meaningful benefits patients are experiencing on therapy, including diet liberalization, cognitive function, and mood improvements.
Frequently Asked Questions About PTCT
When is PTC Therapeutics's next earnings date?
PTC Therapeutics's next earnings report is expected for Feb 17, 2027.
Did PTCT beat earnings estimates last quarter?
Yes. PTC Therapeutics reported EPS of $0.61 for the quarter ended Sep 30, 2026, above the $0.17 estimate, a 258.82% surprise.
What EPS do analysts expect from PTCT next quarter?
The consensus EPS estimate for PTC Therapeutics for the quarter ending Dec 31, 2026 is $0.40 from 17 analysts, with estimates from $0.09 to $0.94.
How often does PTCT beat earnings estimates?
PTC Therapeutics beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +106.03%.
PTCT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors